EP05.02-021 An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC

Abstract

We initiated a prospective, single-arm, phase II study to explore the efficacy, safety, and feasibility of neoadjuvant toripalimab plus platinum-doublet chemotherapy in treatment-naive patients with potentially resectable non-small cell lung cancer (NSCLC). The preliminary results of the study have been presented in 2021 WCLC poster 15.02. Here we report updated data (ClinicalTrials.gov: NCT04144608).